Prostaglandin E2 (PGE2) vaginal gel for cervical ripening

Eur J Obstet Gynecol Reprod Biol. 1991 Feb 25;38(3):197-202. doi: 10.1016/0028-2243(91)90291-r.

Abstract

Cervical ripening prior to oxytocin stimulation is highly desirable to ensure a successful induction. Prostaglandin E2 has been administered by intracervical, intravaginal and extra-amniotic routes with successful ripening of the cervix. The dose of PGE2 administered is under investigation. Use of 3 or 4 mg of PGE2, although effective, has been reported to be accompanied by uterine hypertonus or fetal heart changes. Lower dose of PGE2 at 0.2 mg and 0.4 mg do not have the above-mentioned side effects but necessitate multiple applications. This randomized double-blinded study incorporated the use of 2 mg of PGE2 administered by intravaginal route in a hydroxyethyl cellulose gel medium. A significant increase in Bishop score (40% higher) was achieved in patients receiving PGE2 as compared to placebo patients. There were no adverse side effects, indicating application of 2 mg of PGE2 as a safe method of cervical ripening prior to induction of labor.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Cervix Uteri / drug effects*
  • Dilatation*
  • Dinoprostone / pharmacology*
  • Double-Blind Method
  • Female
  • Gels / pharmacology
  • Humans
  • Labor, Induced*
  • Oxytocin / pharmacology
  • Pessaries*
  • Pregnancy
  • Random Allocation
  • Risk Factors

Substances

  • Gels
  • Oxytocin
  • Dinoprostone